Research on new treatment for vocal fold paralysis
Writer
YesonVoiceCenter
Date
07-04-30 00:00
View
10782
Hyung-tae Kim, directors of Yeson Voice Center, presented the treatment results for vocal fold paralysis using the new biocompatible augmentation materials of Calcium Hydroxylapatite at the 81st Congress of Korean Society of Otorhinolaryngology-Head and Neck Surgery. The 81st Korean Society of Otorhinolaryngology Autumn Congress was held at Grand Hilton Hotel, Seoul from April 27 to 29, 2007.
The title and contents of the paper are as follows. ---------------------------------------------------------------------
Document title: The preliminary study of transcutaneous injection laryngoplasty using Calcium hydroxylapatite (CaHA) in vocal fold paralysis
Objective: Vocal fold paralysis is a glottic chink caused by many factors. The objective of this document is to find the effectiveness of Calcium hydroxylapatite (CaHA) as a new biocompatible augmentation material for vocal fold paralysis.
Method: Out of the 408 patients who had been treated for vocal fold paralysis at Yeson Voice Center, 43 patients who received injection laryngoplasty using CaHA from September, 2006 to January, 2007 were enrolled in this study. The patients were followed for an average period of 3 months, and they were evaluated through audiological voice assessment and VHI, voice analysis and the mucosal wave test, and the voice satisfaction was measured. Significance test was done through ANOVA.
Results: The average age of the vocal fold paralysis patients treated with CaHA was 44 (14-77), and the male to female ratio was 28:15. The causes for vocal fold paralysis included surgical factors (58.8%), unknown reasons (23.5%), accidental factors (5.9%), cranial nerve diseases (4.9%), and miscellaneous (6.9%). Audiological voice evaluation after surgery showed improvement in significance test. Subjective satisfaction of patients showed ‘highly satisfactory’ in 76% (33 cases), satisfactory in 12% (5 cases), and unsatisfactory in 12% (5 cases). Improvements showed in aerodynamic studies along with Jitter and Shimer, and HNR. CaHA showed great convenience in vocal fold injection, and its efficiency in glottic chink and mucosal membrane was greater than PMMA. No complications were observed.
Conclusion: CaHA is a safe, new biocompatible augmentation material which is used in transcutaneous injection laryngoplasty for treating vocal fold paralysis. It is considered to be a very useful augmentation material for improvements in voice and treatment.